Technical Data Sheet

Kit for the Preparation of ^{99m}Tc-Duramycin

Cat # D-1007

Product Description: This cold kit formulation is optimized for the preparation of the small peptide radiopharmaceutical, ^{99m}Tc-duramycin. The active ingredient in the kit is HYNIC-duramycin (Figure 1) in which the HYNIC chelator is attached to amino groups of duramycin. The conjugate contains 1 HYNIC molecule per duramycin molecule. Duramycin binds phosphatidylethanolamine (PE) at a 1:1 ratio with high affinity (K_d of 4-6 nM) and exclusive specificity.

Applications: ^{99m}Tc-duramycin has been shown to be useful for *in vivo* SPECT imaging in animal models of sites where PE is exposed such as during apoptosis [*Zhao, 2008*]. In the cardiovascular area, ^{99m}Tc-duramycin has been shown to be taken up in experimental models of myocardial infaction (MI) [*Wang, 2015; Liu, 2016; Kawai, 2017*], areas of artherosclerotic plaque [*Liu, 2016; Hu, 2017; Kawai, 2017*] and for imaging cardiotoxicty injury [*Nakahara, 2017*]. In the oncology area, it has been shown to allow early prediction of tumor response to therapy [*Elvas, 2015 & 2016; Luo, 2016*] therefore may be used as a screening tool for in vivo evaluation of new cancer drugs. It has also been used for whole body imaging to detect tissue injury from ionizing irradiation [*Johnson, 2013*] and may be useful to detect organ toxicity from known and experimental drug treatments [*Kawai, 2017*].

Fig 1: Chemical structure of HYNIC-duramycin



Product Formulation Procedure: For radiolabeling, ~ 30 mCi of ^{99m}Tc-pertechnetate in 0.5mL saline is added to the vial and excess vial pressure vented. The vial is then heated at 80°C in a lead-lined heating block for 30 mins and the radiolabel incorporation and radiochemical purity is assessed either by ITLC or radio-HPLC analysis [*Elvas, 2015; Luo, 2016; Zhao, 2012*]. Typical radiopurity of ^{99m}Tc-duramycin is >95%. Typical doses per rat and mouse are ~3-5 mCi and 1 mCi respectively.

Blood Clearance Kinetics: The half-life for the fast clearance α-phase is ~3.6-4.1 mins whereas that of slow clearance β-phase is ~171-180 mins [*Wang, 2015; Luo, 2016*]

Catalog #	Product Name	Size	Price (USD)
D-1007	HYNIC-duramycin- Kit	15 ug (~4-5 rats doses)	$299.00

References:

1. Zhao M et al., J. Nucl. Med. 49 (8), 1345-1352 (2008) 2. Wang L. et al. Nucl. Med. Biol. 42, 198-204 (2015) 3. Liu Z. et al. Nucl. Med. Biol., 43, 496-505 (2016) 4. Kawai H et al. in press (2017) 5. Hu Y et al. in press (2017) 6. Nakahara T et al. in press (2017) 7. Elvas F. et al., Mol. Imag. Biol. 17:838-847 (2015) 8. Elvas F et al., J. Nucl. Med. 57:805-811 (2016) 9. Luo R et al., Mol. Imaging, 15, 1-10 (2016) 10. Johnson SE et al. J. Nucl. Med. 54: 1397-1403 (2013) 11. Zhao M et al., Nucl. Med. Biol. 39: 1006-1011 (2012)

For further information or to place an order please contact Dr. Brian Gray by email: briangray@mtarget.com or phone: 610-738-7938

MOLECULAR TARGETING TECHNOLOGIES, INC.

M · T · T · I

833 Lincoln Ave., Unit 9West Chester, PA 19380
P: 610.738.7938 F: 610.738.7928
Contact us: info@mtarget.com; www.mtarget.com

Version 1: 2 Jan 2017